Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian twin cities retinopathy of prematurity screening database report number 5

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 98, Issue 4, 2013, Pages

  Jalali, Subhadra ^a   Balakrishnan, Divya ^a   Zeynalova, Zarifa ^a,b   Padhi, Tapas Ranjan ^a   Rani, Padmaja Kumari ^a  

^a L V PRASAD EYE INSTITUTE   (India)

^b Department of Retina   (Azerbaijan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TOBRAMYCIN;

ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; INDIAN; INFANT; INTRAOCULAR HEMORRHAGE; LASER SURGERY; LIVER DYSFUNCTION; LONG TERM CARE; MONOTHERAPY; NEWBORN; OPTIC NERVE ATROPHY; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA DETACHMENT; RETINA MACULA HOLE; RETINA TEAR; RETROLENTAL FIBROPLASIA; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCREENING; SIDE EFFECT; SPASTICITY; THERAPY EFFECT; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; TWINS; VISION SALVAGE; VITREORETINAL SURGERY;

NEONATOLOGY; OPHTHALMOLOGY; PAEDIATRIC PRACTICE; THERAPEUTICS; VASCULAR DISEASE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DRUG-INDUCED LIVER INJURY; EYE DISEASES; HUMANS; INDIA; INFANT, NEWBORN; INJECTIONS, INTRAOCULAR; LASER COAGULATION; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84879501881     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2012-302365     Document Type: Article

References (25)

1. Early Treatment for Retinopathy of prematurity Cooperative group. Revised indications for treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.
2. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Ophthalmological outcomes at 10 years. Arch Ophthalmol 2001;119:1110-18.
3. Jalali S, Kesarwani S, Hussain A. Outcomes of a protocol-based management for zone I retinopathy of prematurity. The Indian twin cities retinopathy of prematurity screening program report number 2. Am J Ophthalmol 2011;151:719-24.
4. Fleck BW, McIntosh N. Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev 2008;84:83-8.
5. Miciell A, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab in severe retinopathy of prematurity. Am J Ophthalmol 2008;148:536-42.
6. Mintz-Hittner HA, Kuffel RR. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831-8.
7. Jalali S, Matalia J, Hussain A, et al. Modification of screening criteria for retinopathy of prematurity in India and other middle income countries. Am Jl Ophthalmol 2006;141:966-8.
8. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol 1984;102:1130-4.
9. International committee for the classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991-9.
10. Jalali S, Anand R, Kumar H, et al. Programme planning and screening strategy in retinopathy of prematurity. Ind J Ophthalmol 2003;51:89-99. (Pubitemid 36402164)
11. Jalali S, Azad RV, Trehan HS, et al. Technical aspects of laser treatment for acute retinopathy of prematurity under topical anaesthesia. Ind J Ophthalmol 2010;58:505-19.
12. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Paed 2009;21:182-7.
13. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;17:603-15.
14. Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after Bevacizumab injection. Arch Ophthalmol 2012;130:1000-6.
15. Hartnett ME. Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. Retina 2003;23:322-9. (Pubitemid 36792976)
16. Lakhanpal RR, Fortun JA, Chan-Kai B, et al. Lensectomy and vitrectomy with and without intravitreal triamcinolone acetonide for vascularly active stage 5 retinal detachments in retinopathy of prematurity. Retina 2006;26:736-40. (Pubitemid 44386093)
17. Wu W, Yeh P, Chen S, et al. Effects and complications of Bevacizumab use in patients with retinopathy of prematurity. A multicentre study in Taiwan. Ophthalmology 2011;118:176-83.
18. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after Bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63:1475-8. (Pubitemid 44547561)
19. Rishi P, Kasinathan N, Sahu C. Foveal atrophy and macular hole formation following intravitreal ranibizumab with or without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration. Clinical Ophthalmol 2011;5:167-70.
20. Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of Bevacizumab for advanced retinopathy of prematurity. Graefes ' Arch Clin Exptl Ophthalmol 2008;246:1061-3.
21. Suk KK, Berrocal AM, Murray TG, et al. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity. J Paediatr Ophthalmol Strabismus 2010;47:e1-4.
22. Atchaneeyasakul L, Trinavarat A. Choroidal rupture after adjuvant intravitreal injection of Bevacizumab for aggressive posterior retinopathy of prematurity. Jl. Perinatology 2010;30:497-9.
23. Brown-Glaberman U, Swar R, Dragovich T, et al. Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: a review of two cases. Community Oncology 2008;5:539-43.
24. Hard A, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment- a review. Acta Paediatrica 2011;100:1523-7.
25. Azad R, Dave V, Jalali S. Use of intravitreal anti-VEGF: retinopathy of prematurity surgeons' in Hamlets' dilemma. Ind J Ophthalmol 2011;59:421-2.